Company intelligence / Profile preview

Linepharma International

London, United Kingdom

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Linepharma International has successfully commercialized the combination of mifepristone and misoprostol for medication abortion in over 25 countries, receiving regulatory approval in Australia (2014), Canada (2015), and Japan (2023), among others. Their products are used for non-surgical termination of early pregnancy[1][5].

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

Local distribution partners in Europe, Asia, Latin America, Australia, Canada, United Kingdom, Japan[1]

Beyond the preview

Go deeper on Linepharma International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Linepharma International.

Explore the full profile